Erenumab
ATC Code
N02CD01
Erenumab
Definition
A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine.
Also known as Aimovig, AMG 334, AMG-334, AMG334, ERENUMAB — per NCIT
Also identified as
- ATC N02CD01 per RXNORM
- NCIT NCIT:C169958 per NCIT
- SCTID 771590007 per RXNORM
- SCTID 771675000 per RXNORM
- UNII I5I8VB78VT per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Migraine | may prevent | MEDRT · Public domain (U.S. Government work) |